IGC Announces Issuance of Patent for the Procedure of Alzheimer’s Illness Making use of THC
POTOMAC, Md., July 22, 2021–(Company WIRE)–India Globalization Funds, Inc. (the “Business”) (NYSE American: IGC) announced nowadays that on July 20, 2021, the United States Patent and Trademark Office (“USPTO”) issued a patent (#11,065,225) for the treatment method of Alzheimer’s illness entitled “Extremely-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Ailment.”
The first patent software was initiated by the University of South Florida (“USF”) and submitted on August 1, 2016. On Could 25, 2017, IGC entered into an distinctive license settlement with USF with regard to the patent application and the associated investigate carried out on Alzheimer’s disease.
The granted patent relates to IGC’s proprietary formulation meant to guide in the treatment of people today living with Alzheimer’s disorder. IGC’s proprietary formulation, IGC-Ad1, is the subject matter of the Company’s beforehand-disclosed Period 1 medical trial. The Organization not too long ago announced the completion of Cohort 3 in its placebo-managed Various Ascending Dose (MAD) phase 1 demo for setting up protection and tolerability of IGC-Ad1 that works by using THC on individuals suffering from Alzheimer’s ailment.
This push launch includes forward-wanting statements inside of the meaning of Portion 21E of the Securities Exchange Act of 1934. These ahead-searching statements are based mostly on IGC’s expectations and are topic to numerous threats and uncertainties, specified of which are further than IGC’s control. Real results could vary materially from these ahead-on the lookout statements as a consequence of, amid other things, the Company’s failure or inability to commercialise 1 or much more of the Company’s products or systems, like the investigational new drug or formulation explained in this launch, or failure to get hold of Food and drug administration acceptance for the investigational new drug screening benefits from human scientific trials that may not be favorable or as predicted normal financial conditions that are a lot less favorable than predicted, including as a end result of the ongoing COVID-19 pandemic the FDA’s standard placement relating to hashish- and hemp-centered products and solutions and other variables, a lot of of which are mentioned in IGC’s SEC filings. IGC incorporates by reference the human demo disclosures and Possibility Variables recognized in its Yearly Report on Kind 10-K submitted with the SEC on June 14, 2021, as if thoroughly integrated and restated herein. Taking into consideration these dangers and uncertainties, there can be no assurance that the forward-on the lookout facts contained in this launch will take place.
India Globalization Funds, Inc. (IGC) engages in the advancement of cannabinoid-dependent therapies for indications such as Alzheimer’s illness and agony. It operates in two traces of business, Infrastructure and Existence Sciences and is headquartered in Potomac, MD.
www.igcinc.us, www.igcpharma.com, Twitter @IGCIR.
Watch supply model on businesswire.com: https://www.businesswire.com/news/house/20210722005361/en/
Claudia Grimaldi / 301-983-0998